<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419584</url>
  </required_header>
  <id_info>
    <org_study_id>AD study</org_study_id>
    <nct_id>NCT04419584</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children</brief_title>
  <official_title>A Randomized Placebo-Controlled Clinical Trial of an Innovative Herbal Formula for Atopic Dermatitis in Children: Evaluations of Modified Qing-Ying Decoction on Efficacy and Gut Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the clinical efficacy and safety of the modified Qing-Ying&#xD;
      Decoction (mQYD) for the treatment of subacute and chronic atopic dermatitis (AD) in children&#xD;
      when compared to the placebo control through examining the clinical symptoms, quality of&#xD;
      life, gut microbiome, and Chinese medicine body constitution.&#xD;
&#xD;
      This is a parallel, randomized, placebo-controlled, double-blind clinical trial. Eligible&#xD;
      subjects will be randomly allocated to receive oral mQYD granules or it's placebo granules.&#xD;
      Subjects will have 12-week of treatment, and then a 4-week follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects will come for a screening visit at week 0 (baseline), then at week 6, week 12,&#xD;
      and week 16 for Chinese medicine practitioner (CMP) investigators assessments. Eczema Area&#xD;
      and Severity Index (EASI), Children's Dermatology Life Quality Index (CDLQI),&#xD;
      Patient-Oriented Eczema Measure (POEM), and Chinese Medicine body constitution types will be&#xD;
      assessed and filled up at different timepoints. They will receive oral herbal mQYD or placebo&#xD;
      granules for 12 weeks and then be followed up 4 weeks after the treatment. Registered CMPs&#xD;
      will provide consultation under Chinese medicine theory. Study medication compliance and&#xD;
      adverse events will also be assessed at each visit. Besides, they need to record the food&#xD;
      taken in a diary before the day for taking faecal specimen for gut microbiome analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eczema Area and Severity Index (EASI)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Min value: 0, max value: 72, higher scores mean worse outcome. To assess the severity of atopic dermatitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Oriented Eczema Measure (POEM)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Min value: 0, max value: 28, higher scores mean worse outcome. To assess the subjective symptoms of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Dermatology Life Quality Index (CDLQI)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Min value: 0, max value: 30, higher scores mean worse outcome. To assess the quality of life of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constitution of Chinese Medicine Questionnaire (CCMQ)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Not a scale. Based on the answers, a logarithm will be used to determine the type of Chinese Medicine Constitution of the subjects. To assess the Chinese medicine body constitution of subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Modified Qing-Ying Decoction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herbal granules, twice per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Identical looking placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo granules, twice per day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified Qing-Ying Decoction</intervention_name>
    <description>Herbal granules</description>
    <arm_group_label>Modified Qing-Ying Decoction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Identical looking placebo</intervention_name>
    <description>Placebo granules</description>
    <arm_group_label>Identical looking placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of 4 to 17 (Chinese only);&#xD;
&#xD;
          2. With EASI â‰¥ 10;&#xD;
&#xD;
          3. Subacute and chronic atopic dermatitis presenting with dry, scaly, erythematous&#xD;
             papules and plaques; and&#xD;
&#xD;
          4. Provide written informed consent form (signed by one of their parents)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to Chinese medicines;&#xD;
&#xD;
          2. AD with Yang deficiency in syndrome differentiation, such as pale looking, always&#xD;
             feeling cold, fatigue, chronic diarrhea with loose stool, urinary disorders such as&#xD;
             urinary difficulty, excessive urination or incontinence&#xD;
&#xD;
          3. Known overt bacterial infections in the skin;&#xD;
&#xD;
          4. Known pregnancy;&#xD;
&#xD;
          5. Known severe medical conditions, such as cardiovascular, liver or renal dysfunction or&#xD;
             Diabetes Mellitus;&#xD;
&#xD;
          6. Having used oral corticosteroids, oral antibiotics, other immunosuppressive or any&#xD;
             preparation of oral herbal medicines for the treatment of AD in the past month;&#xD;
&#xD;
          7. Having been diagnosed with scabies, allergic contact dermatitis, seborrheic dermatitis&#xD;
             or psoriasis; and&#xD;
&#xD;
          8. Has taken anti-coagulant or anti-platelet drugs in the past month.&#xD;
&#xD;
          9. Has taken any probiotics, prebiotics in the last month&#xD;
&#xD;
         10. Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-xiu Lin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chi-him Sum</last_name>
    <phone>39433438</phone>
    <email>chsum@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-xiu Lin, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Prof. Lin Zhixiu</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

